Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis by 김병모
 International Journal of 
Molecular Sciences
Article
Thymoquinone Selectively Kills Hypoxic Renal
Cancer Cells by Suppressing
HIF-1α-Mediated Glycolysis
Yoon-Mi Lee 1,†, Geon-Hee Kim 2,3,†, Eun-Ji Park 2, Taek-In Oh 2,3, Sujin Lee 2,3,
Sang-Yeon Kan 2,3, Hyeji Kang 2,3, Byeong Mo Kim 4, Ji Hyung Kim 5 and Ji-Hong Lim 2,3,*
1 Department of Food Bioscience, College of Biomedical & Health Science, Konkuk University, Chungju 27478,
Korea; yoonmilee@kku.ac.kr
2 Department of Biomedical Chemistry, College of Biomedical & Health Science, Konkuk University,
Chungju 27478, Korea; rlarjsgml4@kku.ac.kr (G.-H.K.); peunji0503@kku.ac.kr (E.-J.P.);
dk1050@kku.ac.kr (T.-I.O.); 201341532@kku.ac.kr (S.L.); hsb6477@kku.ac.kr (S.-Y.K.); kkang@kku.ac.kr (H.K.)
3 Diabetes and Bio-Research Center, Konkuk University, Chungju 27478, Chungbuk, Korea
4 Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases (SIRIC),
Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Korea; bkim2@yuhs.ac
5 College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea; jay_kim@korea.ac.kr
* Correspondence: jhlim@kku.ac.kr; Tel.: +82-43-840-3567; Fax: +82-43-840-3929
† These authors contributed equally to this work.
Received: 7 February 2019; Accepted: 25 February 2019; Published: 3 March 2019


Abstract: Several reports have shown that thymoquinone (TQ) effectively attenuates angiogenesis
in cancer cells, resulting in suppression of tumor growth. However, it is not yet clear whether
TQ reduces hypoxia-inducible factor-1α (HIF-1α) expression in hypoxic cancer cells. Here, we
found that TQ was a novel HIF-1α inhibitor through hypoxia response element (HRE)-luciferase
assay-based large screening by using 502 natural compounds containing chemical library. TQ reduced
HIF-1α protein levels in renal cancer cells; however, it did not affect the HIF-1α protein levels in
the presence of proteasome inhibitor, MG132, indicating that the reduction effects of TQ on HIF-1α
protein are mediated via the ubiquitination-proteasome dependent pathway. TQ boosted HIF-1α
protein degradation, and the mechanism was revealed by inhibiting interaction between HSP90 and
HIF-1α. TQ suppressed downstream genes of HIF-1α, indicating negative impact of TQ on HIF-1α
transcriptional activities. In addition, TQ altered glucose, lactate, and ATP levels, leading to anaerobic
metabolic disturbance. TQ induced apoptosis in hypoxic cancer cells as determined by crystal violet
staining and flow cytometry for annexin V-stained cells. Taken together, we suggested that TQ is a
potential anticancer agent targeting HIF-1α.
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1. Introduction
Renal cancer has been highly ranked as a cancer exhibiting serious malignancy and poor prognosis
due to its metastatic characteristics and resistance to chemotherapy or radiotherapy in renal cancer
patients [1]. Although cytokine-based therapy or vascular endothelial growth factor receptor (VEGFR)
inhibitors have been used to treat metastatic renal cancer, the trials did not convincingly suggest
a complete cure [1,2]. Thus, more effort is needed for the development of effective therapeutic
approaches to treat renal cancer.
Thymoquinone (TQ) is a major bioactive component of Nigella sativa, also called as black seed
or black cumin, and it exerts health benefits via anti-oxidant, anti-inflammatory, anti-microbial,
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and anti-diabetic effects [3]. In addition, TQ also exhibited protective functions against several
pathophysiological disorders, such as cancer and neurodegenerative diseases [3–6]. In particular,
several reports have demonstrated that TQ can be used as a potential agent against cancer by inhibiting
proliferation, angiogenesis, migration, and invasion in various cancer cells [7]. Taking into account
the anti-cancer mechanism, TQ inhibits phosphorylated mitogen-activated protein kinase (MAPK),
Akt, and mammalian target of rapamycin (mTOR) involved in tumorigenesis signaling pathway.
Oncogenic transcription factors, such as nuclear factor-κB (NF-κB) and signal transducer and activator
of transcription 3 (STAT-3), were downregulated, while carcinogen-metabolizing enzymes, such as
cytochrome p450 1A2 (CYP 1A2) and cytochrome p450 3A4 (CYP 3A4), were upregulated by TQ [8].
However, the effects of TQ on HIF-1α action have not been elucidated.
In cancer, hypoxic condition is a common occurrence due to increased oxygen consumption
resulting from rapidly growing cells, thus leading to HIF-1α activation. HIF-1α exacerbates tumor
growth upon oxygen and nutrient deprivation through transcriptional reprogramming of angiogenesis,
anaerobic glycolysis, and invasiveness [9]. HIF-1α is associated with high incidence of cancer, poor
prognosis, and resistance to chemotherapy or radiotherapy in cancer patients. Thus, extensive studies
have demonstrated that targeting HIF-1α could be a promising anti-cancer therapeutic strategy [10].
Under normoxic condition, HIF-1α protein is hydroxylated by prolyl hydroxylase (PHD),
recognized by E3 ligase complex, mainly containing Von-Hippel Lindau protein (pVHL), and is
consequently ubiquitinated and destroyed in the 26S proteasome. Since the hydroxylation does not
occur under hypoxic condition, HIF-1α can be stabilized. The stabilized HIF-1α enters into nucleus, and
dimerizes with HIF-1β, which is constitutively expressed in the nucleus. The heterodimer recognizes
hypoxia response element (HRE) containing downstream genes. Then, genes aggravating the cancer
are expressed by transcriptional activators, such as p300 and CREB binding protein (CBP) [11].
HSP90 is known to stabilize HIF-1α protein independent of pVHL-mediated ubiquitination.
Geldanamycin, an HSP90 inhibitor, induced HIF-1α degradation, thus leading to a reduction in
transcriptional activity of HIF-1α [12]. Other HSP90 inhibitors, such as 17-AAG and 17-DMAG, have
also been shown to reduce HIF-1α protein levels and its transcriptional activities [13]. The anticancer
activity of HSP90 inhibitors has been studied, and targeting HIF-1α can be one of the possible
molecular mechanisms.
Because of oxygen deprivation and poor vascularization, rapidly growing cancer cells fail
to undergo oxidative phosphorylation, the most effective way to generate ATP after glycolysis.
Thus, increased glycolysis for generating ATP utilized for biosynthesis of biomass, such as amino
acids, lipids, and nucleotides is an inevitable metabolic reprogramming which causes rapid growth
in cancer cells [14]. HIF-1α plays a pivotal role in this metabolic disturbance by elevating the
expression of genes involved in glycolysis and glucose transport [15]. Such metabolic reprogramming
confers an opportunity for cancer cells to survive under oxygen and nutrient deprivation condition.
Pharmacological inhibitors targeting glycolysis are being widely studied, and several glycolysis
inhibitors, such as 2-deoxyglucose and Lonidamine, are being explored in the clinical trial studies [16].
In addition, many studies targeting glycolysis are in the preclinical stage [17].
In the present study, we hypothesized that TQ is a potential anti-cancer drug targeting HIF-1α.
We investigated whether TQ is sufficient to suppress HIF-1α activity, and what is its molecular
mechanism of action in hypoxic renal cancer cells.
2. Results and Discussion
2.1. Thymoquinone (TQ) is a Potential HIF-1α Inhibitor
Since the development of an HIF-1α inhibitor would be beneficial for cancer therapy, we attempted
to identify a potential HIF-1α inhibitor using an HIF-1α-binding sequence containing a hypoxia
responsive element (HRE) by conducting a luciferase assay on a library of 502 natural compounds.
Here, we identified 18 compounds that suppressed HRE luciferase activity to lower than 50% under
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hypoxia (Figure 1A). An additional luciferase assay to validate the larger screening also showed that 18
compounds suppressed hypoxia-induced HRE luciferase activities (Figure 1B). Although many of these
compounds, including genestein [18], caffeic acid [19], curcumin [20], CAPE [21], epigallocatechin [22],
etoposide [23], rapamycin [24], quercetin [25], resveratrol [26], fisetin [27], radicicol [28], wogonin [29],
and honokiol [30] have been identified previously as HIF-1α inhibitors, thymoquinone (TQ) was
identified as a novel HIF-1α inhibitor (Figure 1B). In addition, Figure 1C shows that TQ suppressed
HIF-1α-binding sequence exhibiting VEGF promoter activity (bottom panel) as well as HRE luciferase
activity (upper panel) in Caki-1 renal cancer cells under hypoxia. These results revealed that TQ is a
potential HIF-1α inhibitor. Although previous reports have shown the anti-angiogenic effect of TQ
in cancer, its regulatory mechanism was not clearly elucidated [31]. Here, based on our findings, we
can elucidate the unknown regulatory mechanism of TQ-mediated suppression of angiogenesis via
HIF-mediated VEGF expression.
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Figure 1. Luciferase assay-based large screening of natural compounds that inhibited Hypoxia-
inducible factor-1α (HIF-1α). (A) HEK293 cells, transiently expressing HRE-luciferase vector, were 
incubated with 502 natural compounds dissolved in dimethyl sulfoxide (DMSO). Each compound 
was used at final concentration of 10 μM for 24 h under hypoxia. (B) HEK293 cells expressing HRE-
luciferase vector were incubated with 10 μM of 18 compounds for 24 h. The values represent the mean 
± SD of three independent experiments performed. (C) HRE- and VEGF-luciferase vector was 
transiently transfected into Caki-1 cells, and then incubated for 24 h to allow stabilization. Cells were 
further incubated with 10 μM of TQ for 24 h under normoxia or hypoxia. Luciferase activities were 
normalized using β-gal assay. The values represent the mean ± SD of three independent experiments 
performed in duplicate; * p < 0.05 and ** p < 0.01. 
2.2. TQ Decreases HIF-1α in Hypoxic Renal Cancer Cells 
Natural compound screening to identify a potential HIF-1α inhibitor showed that TQ is 
sufficient to reduce HIF-1α transcriptional activity (Figure 1). In addition, previous reports have 
shown that TQ suppresses VEGF-mediated angiogenesis during cancer growth [32]. Thus, here we 
investigated whether hypoxia-inducible factor-1α (HIF-1α) might be a potential target of TQ in renal 
cancer cells. Initially, we found that TQ efficiently decreases HIF-1α protein levels in a dose-
dependent manner in hypoxic Caki-1, Caki-2, A498, and flag-tagged pVHL expressing RCC4 cells 
Figure 1. Luciferase assay-based large screening of natural compounds that inhibited Hypoxia-inducible
factor-1α (HIF-1α). (A) HEK293 cells, transiently expressing HRE-luciferase vector, were incubated
with 502 natural compounds dissolved in dimethyl sulfoxide (DMSO). Each compound was used at
final concentration of 10 µM for 24 h under hypoxia. (B) HEK293 cells expressing HRE-luciferase vector
were incubated with 10 µM of 18 compounds for 24 h. The values represent the mean ± SD of three
independent experiments performed. (C) HRE- and VEGF-luciferase vector was transiently transfected
into Caki-1 cells, and then incubated for 24 h to allow stabilization. Cells were further incubated with
10 µM of TQ for 24 h under normoxia or hypoxia. Luciferase activities were normalized using β-gal
assay. The values represent the mean ± SD of three independent experiments performed in duplicate;
* p < 0.05 and ** p < 0.01.
2.2. TQ Decreases HIF-1α in Hypoxic Renal Cancer Cells
Natural compound screening to identify a potential HIF-1α inhibitor showed that TQ is sufficient
to reduce HIF-1α transcriptional activity (Figure 1). In addition, previous reports have s own that
TQ suppresses VEGF-mediated angioge esis during cancer growth [32]. Thus, here we investigated
whether hypoxia-inducible factor-1α (HIF-1α) mi ht be a potential target of TQ in renal canc cells.
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Initially, we found that TQ efficiently decreases HIF-1α protein levels in a dose-dependent manner
in hypoxic Caki-1, Caki-2, A498, and flag-tagged pVHL expressing RCC4 cells (RCC4 + pVHL)
(Figure 2A,B). In addition, decreased HIF-1α levels in both cytoplasm and nucleus after treatment
with 10 µM of TQ were observed in Caki-1 cells (Figure 2C). These results indicated that TQ decreases
HIF-1α protein levels in hypoxic renal cancer cells.
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Figure 2. Hypoxia-inducible factor-1α (HIF-1α) is decreased by thymoquinone (TQ) in hypoxic renal
cancer cells. (A) Caki-1 and A498 renal cancer cells were incubated with various concentrations of
TQ (0, 1, 2, 5, or 10 µM) as indicated for 8 h under hypoxia. Protein expression levels were measured
by western blotting as described in Materials and Methods. (B) RCC4 + pVHL and Caki-2 cells were
incubated with TQ as indicated upon hypoxia for 8 h. (C) Caki-1 cells treated with 10 µM of TQ upon
normoxia or hypoxia for 8 h were used for obtaining cytoplasmic or nuclear protein samples. Nuclear
proteins were isolated using high concentration of sodium chloride-based hypertonic buffer. β-tubulin
and lamin B proteins were used as a loading control for cytoplasmic proteins and nuclear proteins.
2.3. TQ Decreases HIF-1α Expression Independent of PHD-Mediated Hydroxylation but Dependent on
Proteasomal Degradation Pathway
Under hypoxia, HIF-1α is degraded via PHDs-mediated hydroxylation and Von-Hippel Lindau
protein (pVHL)-mediated polyubiquitination [11]. Prolyl hydroxylases (PHDs), including PHD1, 2,
and 3, enzymatically cause hydroxylation of HIF-1α on proline 402 and 564 residues with co-factors,
such as α-ketoglutarate and iron. Dimethyl xaloylglycine (DMOG) and deferoxamine (DFO) are used
s PHD inhibi or and iron chelator, respectively. Hydroxylat d HIF-1α interacts with pVHL as an
E3-ubiquitin li ase, resulting in polyubiquitin tion-mediated proteasome-dependent degradation,
which is blocked by 26S proteasome inhibitor, MG132 (Figure 3A). To underst nd the molecul r
mechanism by which TQ suppresses HIF-1α, we initially investigated whether TQ also decreases
HIF-1α induced by suppression of hyd xylation. HIF-1α increased by DFO (Figure 3B) or DMOG
(Figure 3C) was also significantly decreased in TQ-treated Cak -1 cells, indicating that TQ does not
affect PHDs and iron-me iated HIF-1α hydrox lation. In addition, no alter tion of PHD1, 2, and 3 was
observed in TQ-treated Caki-1 and Caki-2 cells (Figure 3D). Since polyubiquitinated HIF-1α is degraded
by 26S prot asome pathway [10], we further investigated whether TQ suppresses MG132-induced
HIF-1α. Figure 3E shows that TQ was not sufficient to decrease HIF-1α protein levels accumul
by MG132, demonstrating tha TQ ay decre se HIF-1α via the proteasome-dependent degradation
pathway. An E3-ubiquitin ligase, pVHL, is an important factor involved in polyubiquitination of
HIF-1α [10]. Thus, we investigated whether TQ affecte pVHL-mediated polyubiquitination of HIF-1α.
Here, we found at loss of VHL was sufficient to increase HIF-1α levels under normoxic conditio
in RCC4 cells, and TQ significantly decreas d HIF-1α l vels in VHL-null RCC4 cells (Figure 3F).
T investigate whether TQ affects HIF-1α hydroxylation under normoxia or hypoxia, hydroxylated
HIF-1α (OH-HIF-1α) was measured. Figure 3G shows that hydroxylated HIF-1α was not altered by
TQ treatment. These results suggested that TQ suppresses IF-1 via the proteasome-dependent
pathway, but not indep ndent of hydroxylation and pVHL-mediated polyubiquitination pathways.
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protein synthesis was observed in TQ-treated VHL-null RCC4 cells, suggesting that reduction in HIF-
1α levels in TQ-treated cells is caused by altered degradation pathway (Figure 4A). However, HIF-
1α protein accumulation by MG132 was not altered in TQ-treated cells, indicating that de novo 
synthesis of HIF-1α is not linked to TQ-mediated HIF-1α suppression (Figure 4B). HIF-1α stability is 
mainly regulated by pVHL-mediated polyubiquitination and HSP90-mediated stabilization [12]. 
HSP90 inhibitors, such as geldanamycin and radicicol, hindered interaction between HSP90 and HIF-
1α, leading to ubiquitin-mediated destabilization of HIF-1α protein [33]. In Figure 4C, we further 
investigated an interplay between TQ-mediated HIF-1α degradation and HSP90-mediated HIF-1α 
stabilization. Interestingly, we found that TQ significantly interfered in physical interaction between 
HIF-1α and HSP90 (Figure 4C). To confirm whether suppression of HIF-1α by TQ is dependent on 
HSP90-mediated HIF-1α stabilization, TQ effect was measured in the absence or presence of 
geldanamycin (GA), a selective HSP90 inhibitor. Here, further decreased HIF-1α was not observed 
under TQ and GA treatment, suggesting that suppression of HIF-1α by TQ may be connected to 
Hsp90-mediated HIF-1α stabilization (Figure 4D). These results indicated that HSP90-mediated HIF-
Figure 3. TQ suppresses HIF-1α via the proteasome-dependent degradation pathway. (A) Schematic
summary of HIF-1α hydroxylation and its proteasome-dependent degradation pathway. Deferoxamine
(DFO), as an iron chelator, inhibits HIF-1α hydroxylation. Dimethyloxaloylglycine (DMOG), as a PHDs
inhibitor, suppresses HIF-1α hydroxylation. MG132, as a 26S proteasome inhibitor, blocks HIF-1α
ubiquitination-mediated degradation. (B,C) Caki-1 cells were incubated with 10 µM of TQ for 1 h,
and then, cells were further incubated for 8 h in the absence or presence of 100 µM of DFO or 0.5 mM
of DMOG. (D) Caki-1 and Caki-2 cells were cultured with various concentrations of TQ (5, 10, and
20 µM) for 8 h, and then, PHD protein levels were analyzed by western blotting. (E) Caki-1 cells were
incubated with 10 µM of TQ for 1 h, and then, the cells were further incubated for 6 h in the absence
or presence of 20 µM of MG132. (F) VHL-null RCC4 (−VHL) and RCC4 (+VHL) cells transiently
expressing Flag-tagged VHL were incubated for 8 h with 10 µM of TQ under normoxia. (G) Caki-1
cells were incubated with 10 µM of TQ for 1 h, and then, cells were further incubated for 8 h under
normoxia or hypoxia. Hydroxylated HIF-1α is measured by using western blotting.
2.4. TQ Suppresses HSP90-Mediated HIF-1α Stabilization
Figure 3E indicates that TQ decreases HIF-1α levels through the proteasome-dependent
degradation pathway. To understand how TQ regulates proteasome-dependent degradation of
HIF-1α, we initially evaluated HIF-1α degradation after blocking protein synthesis in the absence
or presence of TQ in VHL-null RCC4 cells. Rapid degradation of HIF-1α upon blocking of de novo
protein synthesis was observed in TQ-treated VHL-null RCC4 cells, suggesting that reduction in
HIF-1α levels in TQ-treated cells is caused by altered degradation pathway (Figure 4A). However,
HIF-1α protein accumulation by MG132 was not altered in TQ-treated cells, indicating that de novo
synthesis of HIF-1α is not linked to TQ-mediated HIF-1α suppression (Figure 4B). HIF-1α stability
is mainly regulated by pVHL-mediated polyubiquitination and HSP90-mediated stabilization [12].
HSP90 inhibitors, such as geldanamycin and radicicol, hindered interaction between HSP90 and
HIF-1α, leading to ubiquitin-mediated destabilization of HIF-1α protein [33]. In Figure 4C, we further
investigated an interplay between TQ-mediated HIF-1α degradation and HSP90-mediated HIF-1α
stabilization. Interestingly, we found that TQ significantly interfered in physical interaction between
HIF-1α and HSP90 (Figure 4C). To confirm whether suppression of HIF-1α by TQ is dependent
on HSP90-mediated HIF-1α stabilization, TQ effect was measured in the absence or presence of
geldanamycin (GA), a selective HSP90 inhibitor. Here, further decreased HIF-1α was not observed
under TQ and GA treatment, suggesting that suppression of HIF-1α by TQ may be connected to
Hsp90-mediated HIF-1α stabilization (Figure 4D). These results indicated that HSP90-mediated HIF-1α
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stabilization is a potential target of TQ. Further studies need to unravel the mechanistic action of TQ
on interplay between HIF-1α and HSP90.
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were incubated with 10 μM of geldanamycin (GA) for 8 h in the absence or presence of 10 μM of TQ, 
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hypoxic glycolysis by TQ treatment, increased extracellular lactate levels under hypoxia were 
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Figure 4. TQ causes rapid degradation of HIF-1α by inhibiting interaction between HIF-1α and HSP90.
(A) VHL-null RCC4 cells were incubated with 100 µM of CHX for 0, 1, 2, or 3 h in the absence or
presence of 10 µM of TQ as indicated. After drug treatment, protein levels were measured by western
blotting. (B) Caki-1 cells were pre-incubated with 100 µM of CHX for 5 h, and then, blocking of de novo
protein synthesis was stopped by replacing of culture medium without CHX. Cells were additionally
cultured with 20 µM of MG132 for 0.5, 1, 2, or 4 h in the absence or presence of 10 µM of TQ. (C)
Caki-1 cells were incubated with 20 µM of MG132 for 6 h in the absence or presence of 10 µM of TQ,
and then, total cell lysates were reacted with normal serum or antibodies against for HSP90. After
immunoprecipitation, protein complexes were analyzed by western blotting. (D) Caki-1 cells were
incubated with 10 µM of geldanamycin (GA) for 8 h in the absence or presence of 10 µM of TQ, and
then, HIF-1α protein levels were measured by using western blotting.
2.5. Expression of Tumor Promoting HIF-1α Target Genes is Downregulated by TQ Treatment
HIF-1α in hypoxic cancer cells upregulated expression of genes linked to tumor progression, such
as anaerobic glycolysis (CA-IX, PDK1, GLUT1, and LDHA), metastasis (FN1, LOXL2, and uPAR), and
angiogenesis (VEGF) for cellular adaptation from hypoxic stress [9]. TQ suppressed HIF-1α protein
levels, which significantly downregulated the hypoxia-induced tumor promoting HIF-1α target genes,
such as FN1, LOXL2, uPAR, VEGF, CA-IX, PDK1, GLUT1, and LDHA, in TQ-treated Caki-1 (Figure 4A)
and Caki-2 (Figure 4B) cells. These results suggested that TQ is sufficient to suppress tumor promoting
HIF-1α in hypoxic renal cancer cells.
2.6. TQ Suppresses Anaerobic Glycolysis in Hypoxic Renal Cancer Cells
When cells are exposed to hypoxia, glucose utilization and lactate production is increased through
HIF-1α pathway-mediated anaerobic glycolysis to rapidly fulfill biological demands, such as ATP
and cellular building blocks, which provides an opportunity for survival and proliferation during
metabolic stress caused by hypoxia [13–15]. Thus, it is becoming clear that metabolic reprograming of
hypoxic cancer cells is a potential target for cancer treatment [16]. Based on the fact that TQ is sufficient
to suppress the expression of glycolysis-related genes in hypoxic renal cancer cells (Figure 5), we
investigated whether hypoxia-induced metabolic reprogramming to anaerobic glycolysis is targeted in
TQ-treated renal cancer cells. Initially, we found that glucose level is decreased in Caki-1 and A498
cultured medium under hypoxia, suggesting that hypoxic renal cancer cells are more addictive to
glucose utilization (Figure 6A). Moreover, here we found that TQ significantly increases glucose levels
in hypoxic Caki-1 and A498 cultured medium, indicating that hypoxia-induced anaerobic glycolysis
is significantly suppressed by TQ treatment (Figure 6A). Since, increased glycolysis causes lactate
production in hypoxic cells [13–15], we further investigated whether TQ alters hypoxia-induced
lactate production and secretion. Consistent with suppression of hypoxic glycolysis by TQ treatment,
increased extracellular lactate levels under hypoxia were decreased in TQ-treated Caki-1 and A498 renal
cancer cells (Figure 6B). In addition, intracellular ATP levels were significantly decreased in TQ-treated
Caki-1 and A498 cells under hypoxia (Figure 6C). These results revealed that hypoxia-induced glucose
utilization and lactate production is targeted by TQ in renal cancer cells.
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Figure 5. TQ decreases expression of hypoxia-induced HIF-1α target genes in renal cancer cells.
(A) Caki-1 and (B) A498 cells were incubated under normoxia or hypoxia in the absence or presence
of 10 µM of TQ for 24 h. The values represent the mean ± SD of three independent experiments
performed in duplicate; * p < 0.05 and ** p < 0.01.
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Figure 6. TQ alters glucose-dependent metabolism under hypoxia in renal cancer cells. (A) Glucose
consumption was measured in Caki-1 and A498 renal cancer cells. Cells were incubated with or
without 10 µM of TQ for 24 h under normoxia or hypoxia. (B) Lactate production was evaluated.
Caki-1 and A498 cells were incubated with or without 10 µM of TQ for 24 h under normoxia or hypoxia.
(C) Intracellular ATP levels were measured in Caki-1 and A98 cells in the absence or presence of TQ
under normoxia or hypoxia. The values represent the mean ± SD of three independent experiments
performed in duplicate; * p < 0.05.
2.7. TQ Selectively Pro otes Apo tosis in Hypoxic Renal Cancer Cells
HIF-1α mainly triggers cells to evade death caused by metabolic stress upon hypoxia [34]. Since
the cancer cells adapted against hypoxic stress exhibit ore aggressive behavior, it is necessary
to develop ph rmacologic l inhibit rs that target hypoxic cancer ells [9]. T provide the clinical
application of TQ in cancer treatment, we furth r investig ted whether TQ substantially promotes
a optosis in hypoxic renal cancer cells. Figure 7A shows that TQ significantly dec eased cell viab lity
by approximately 50% under hypoxia in Caki-1 and A498 renal cancer cells. Consistently, an increase
in the degree of apoptosis by over 15% after TQ treatment under hypoxic con ition was observ d in
Caki-1 and A498 renal cancer c lls (Figure 7B,C). Tu or hypoxi is closely related to chemoth r py
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resistance, and HIF-1α induces expressions of multidrug resistance 1 (MDR1) and multidrug resistance
associated protein 1 (MRP 1) genes [35]. Thus, using selective inhibitors targeting hypoxic cancer cells
and HIF-1α is an attractive strategy for development of anticancer agents [36], and several reports have
shown improved efficacy of anticancer drugs by suppressing HIF-1α under hypoxic condition [37].
Our results additionally revealed that TQ is sufficient to selectively kill hypoxic renal cancer cells.
However, further study is needed to validate this action in in vivo.
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3. Materials and Methods
3.1. Reagents and Antibodies
A library of 502 natural compounds was obtained from Enzo Biochem (Farmingdale, NY, USA).
Thymoquinone, MG132, geldanamycin (GA), and cycloheximide (CHX) were purchased from Sigma
Aldrich (St. Louis, MO, USA). Antibodies recognizing HIF-1α (#3716), Pro564-OH-HIF-1α (#3434),
PHD1 (sc-293220), PHD2 (#4835), PHD3 (ab30782), HSP90 (sc-69703), and β-tubulin (sc-9104) were
purchased from Cell Signaling Technology (Danvers, MA, USA), Santa Cruz Biotechnology (Dallas,
TX, USA), and Abcam (Cambridge, MA, USA).
3.2. Cell Culture and Cell Viability Assay
Renal cancer cell lines (Caki-1, Caki-2, A498) were obtained from the Korean Cell Line Bank
(Seoul, Korea) and American Type Culture Collection (Manassas, VA, USA), and cultured in McCoy’s
5A and RPMI1640 supplemented with 10% fetal bovine serum. VHL-null RCC4 cell lines were kind
gift from Dr. Jong-Wan Park [38], and cultured in Dulbecco’s modified Eagle’s medium (DMEM)
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supplemented with 10% fetal bovine serum. Cells were incubated in a humidified atmosphere at
37 ◦C under normoxia (20% O2 and 5% CO2) or hypoxia (1% O2 and 5% CO2). Cell viability assay
was performed using crystal violet staining [39]. Briefly, cells were cultured in 24-well tissue culture
dishes with or without drug treatment. After incubation with drugs, washed cells were fixed using 4%
paraformaldehyde, and then stained with 0.5% crystal violet solution for 20 min at room temperature.
Optical density of crystal violet was analyzed using 1% SDS solution and measured by an absorbance
reader (BioTek, Winooski, VT, USA) (OD570).
3.3. Immunoprecipitation and Western Blotting
For immunoprecipitation, cell lysates were prepared using 0.5% CHAPS, 40 mM HEPES
(pH 7.5), 150 mM NaCl, and a protease and phosphatase inhibitor cocktail containing CHAPS
immunoprecipitation buffer (CIB). One milligram of cell lysates were incubated with 1 µg of antibody
recognizing HSP90 and 20 µL of protein G agarose for 16 h at 4 ◦C. After immunoprecipitation, protein
complexes were denatured with 1× sodium dodecyl sulfate (SDS) sample buffer and boiled at 95 ◦C
for 5 min, and then, protein levels were measured using western blotting. For western blotting, total
crude proteins were prepared using protein extraction buffer (1% IGEPAL, 150 mM NaCl, 50 mM
Tris-HCl (pH 7.9), 10 mM NaF, 0.1 mM EDTA, and a protease inhibitor cocktail). Forty micrograms
of proteins were loaded on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and separated proteins were transferred on PVDF membranes (Millipore, Burlington, MA, USA).
Transferred membranes were incubated with primary antibodies (1:1000–1:5000 dilution) against
target proteins for 16 h at 4 ◦C. After primary antibody reactions, membranes were washed using
Tween 20 containing Tris-buffered saline (TBS-T), and then, they were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibodies (1:10,000) for 1 h at room temperature. For
analyzing expression of target proteins, the Enhanced Chemiluminescence (ECL) Prime kit (GE
Healthcare, Pittsburgh, PA, USA) was used [39].
3.4. Quantitative Real-Time PCR
Quantitative real-time PCR for analyzing mRNA expression was performed using SYBR Green
PCR Master Mix (Applied Biosystems, Waltham, MA, USA) as previously described [39]. The primer
sequences used in the experiment are shown in Table 1.
Table 1. Primer sequences for quantitative real time-PCR.









Apoptotic cell numbers were quantitatively analyzed using Muse™ Annexin V and Dead
Cell kit (Millipore, Burlington, MA, USA) in accordance with a previously described experimental
procedure [39]. Briefly, Caki-1 and A498 cells (1 × 105 cells/well) were seeded and incubated for
24 h to allow stabilization, and then, 10 µM of TQ was treated for 48 h under normoxia or hypoxia.
After TQ treatment, collected cells were stained with 100 µL of Muse™ Annexin V and Dead Cell kit
reagents (Millipore, Burlington, MA, USA) for 20 min at room temperature. Apoptotic cell population
was measured using Mini Flow Cytometry Muse™ Cell Analyzer (Millipore, Burlington, MA, USA).
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3.6. Luciferase Assay
HIF-1α binding hypoxia-response element (HRE) and VEGF promoter containing luciferase vector
(HRE-Luc and VEGF-Luc) were kind gifts from Dr. Jong-Wan Park (Seoul National University) [38].
For luciferase assay, luciferase and β-gal vector were transiently transfected into HEK293 or Caki-1
cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and PolyFect transfection reagent
(Qiagen, Venlo, Netherlands). After hypoxia or drug treatment in transfected cells, luciferase activities
were measured using a Synergy 2 Luminometer (BioTek, Winooski, VT, USA) and normalized by
β-gal assay.
3.7. Measurement of Glucose Consumption, ATP, and Lactate Production
Glucose and lactate levels in cultured medium were quantitatively measured using colorimetric
assay kit (BioVision, San Francisco, CA, USA) as previously described [40]. Briefly, Caki-1 and A498
cells (1 × 105) were cultured in DMEM without phenol red containing high level of glucose for 24 h in
either absence or presence of TQ under normoxia or hypoxia. After incubation, cultured medium was
incubated with 50 µL of glucose or lactate assay solution for 30 min at 37 ◦C upon in dark. Intracellular
ATP levels were measured using colorimetric assay kit (BioVision, San Francisco, CA, USA). Briefly,
Caki-1 and A498 cells (1 × 105) were cultured in DMEM containing high glucose for 24 h with or
without 10 µM of TQ under normoxia or hypoxia, and then, cultured cells were washed and collected
into fresh tube. Collected cells were homogenized in 100 µL ATP assay buffer, and then, 20 µL cell
lysates in ATP assay buffer were incubated with 50 µL reaction mixture for 30 min at room temperature.
After reaction, optical absorbance indicating glucose, lactate, and ATP levels was measured at 570 nm
(OD570) using an absorbance reader (BioTek, Winooski, VT, USA).
3.8. Statistical Analysis
Data are represented as the mean ± standard deviation (SD), and unpaired Student’s t-test and
one-way ANOVA with Tukey posttest were used for statistical analysis. A p value of < 0.05 was
considered statistically significant.
4. Conclusions
The major findings of this study are that 1) thymoquinone (TQ) was identified as an HIF-1α
inhibitor using a 502 natural compound library, 2) TQ suppressed hypoxia-induced HIF-1α by
suppressing HSP90-mediated stabilization and target genes’ expression, 3) TQ alters hypoxic anaerobic
glycolysis and causes metabolic stress, and 4) TQ selectively killed hypoxic renal cancer cells. Overall,
our finding suggested that TQ, as an HIF-1α inhibitor, is a potential natural compound involved in
clearance of hypoxic renal cancer cells.
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Abbreviations
HIF-1α Hypoxia-inducible factor-1alpha
HRE Hypoxia response element
VEGFR Vascular endothelial growth factor receptor
mTOR Mammalian target of rapamycin






HSP90 Heat shock protein 90
CA-IX Carbonic anhydrase 9
PDK1 pyruvate dehydrogenase kinase 1
GLUT1 Glucose transporter 1
VEGF Vascular endothelial growth factor A
LDHA Lactate dehydrogenase A
FN1 Fibronectin 1
LOXL2 Lysyl oxidase homolog 2
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